Search

Your search keyword '"Kreuter A"' showing total 374 results
Start Over Author "Kreuter A" Publisher wiley
374 results on '"Kreuter A"'

1. Thoracic skeletal muscle mass predicts mortality in patients with surgery for pleural empyema: A case control study

Author

Christian Galata, Philipp Schiller, Lukas Müller, Ioannis Karampinis, Davor Stamenovic, Roland Buhl, Michael Kreuter, and Eric Dominic Roessner

Subjects
complications, pleural empyema, prognosis, risk factor, thoracic skeletal muscle mass, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background This study investigated the role of the thoracic skeletal muscle mass as a marker of sarcopenia on postoperative mortality in pleural empyema. Methods All consecutive patients (n = 103) undergoing surgery for pleural empyema in a single tertiary referral center between January 2020 and December 2022 were eligible for this study. Thoracic skeletal muscle mass index (TSMI) was determined from preoperative computed tomography scans. The impact of TSMI and other potential risk factors on postoperative in‐hospital mortality was retrospectively analyzed. Results A total of 97 patients were included in this study. The in‐hospital mortality rate was 13.4%. In univariable analysis, low values for preoperative TSMI (p = 0.020), low preoperative levels of thrombocytes (p = 0.027) and total serum protein (p = 0.046) and higher preoperative American Society of Anesthesiologists (ASA) category (p = 0.007) were statistically significant risk factors for mortality. In multivariable analysis, only TSMI (p = 0.038, OR 0.933, 95% CI: 0.875–0.996) and low thrombocytes (p = 0.031, OR 0.944, 95% CI: 0.988–0.999) remained independent prognostic factors for mortality. Conclusions TSMI was a significant prognostic risk factor for postoperative mortality in patients with pleural empyema. TSMI may be suitable for risk stratification in this disease with high morbidity and mortality, which may have further implications for the selection of the best treatment strategy.

Published
2024
Full Text
View/download PDF

2. Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria

Author

Mareike Tometten, Martin Kirschner, Robert Meyer, Matthias Begemann, Insa Halfmeyer, Margherita Vieri, Kim Kricheldorf, Angela Maurer, Uwe Platzbecker, Markus Radsak, Philippe Schafhausen, Selim Corbacioglu, Britta Höchsmann, C. Matthias Wilk, Claas Hinze, Jörg Chromik, Michael Heuser, Michael Kreuter, Steffen Koschmieder, Jens Panse, Susanne Isfort, Ingo Kurth, Tim H. Brümmendorf, and Fabian Beier

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Telomere biology disorders (TBD) result from premature telomere shortening due to pathogenic germline variants in telomere maintenance-associated genes. In adults, TBD are characterized by mono/oligosymptomatic clinical manifestations (cryptic TBD) contributing to severe underdiagnosis. We present a prospective multi-institutional cohort study where telomere length (TL) screening was performed in either newly diagnosed patients with aplastic anemia (AA) or if TBD was clinically suspected by the treating physician. TL of 262 samples was measured via flow-fluorescence in situ hybridization (FISH). TL was considered suspicious once below the 10th percentile of normal individuals (standard screening) or if below 6.5 kb in patients >40 years (extended screening). In cases with shortened TL, next generation sequencing (NGS) for TBD-associated genes was performed. The patients referred fell into 6 different screening categories: (1) AA/paroxysmal nocturnal hemoglobinuria, (2) unexplained cytopenia, (3) dyskeratosis congenita, (4) myelodysplastic syndrome/acute myeloid leukemia, (5) interstitial lung disease, and (6) others. Overall, TL was found to be shortened in 120 patients (n = 86 standard and n = 34 extended screening). In 17 of the 76 (22.4%) standard patients with sufficient material for NGS, a pathogenic/likely pathogenic TBD-associated gene variant was identified. Variants of uncertain significance were detected in 17 of 76 (22.4%) standard and 6 of 29 (20.7%) extended screened patients. Expectedly, mutations were mainly found in TERT and TERC. In conclusion, TL measured by flow-FISH represents a powerful functional in vivo screening for an underlying TBD and should be performed in every newly diagnosed patient with AA as well as other patients with clinical suspicion for an underlying TBD in both children and adults.

Published
2023
Full Text
View/download PDF

6. S2k guideline: Diagnosis and therapy of localized scleroderma

Author

Kreuter, Alexander, primary, Moinzadeh, Pia, additional, Kinberger, Maria, additional, Horneff, Gerd, additional, Worm, Margitta, additional, Werner, Ricardo N., additional, Hammacher, Andreas, additional, Krieg, Thomas, additional, Wenzel, Jörg, additional, Oeschger, Michael, additional, Weibel, Lisa, additional, Müllegger, Robert, additional, and Hunzelmann, Nicolas, additional

Published
2024
Full Text
View/download PDF

9. Visible‐Light‐Triggered Photoswitching of Diphosphene Complexes

Author

Taube, Clemens, primary, Fidelius, Jannis, additional, Schwedtmann, Kai, additional, Ziegler, Christopher, additional, Kreuter, Florian, additional, Loots, Leigh, additional, Barbour, Leonard J., additional, Tonner‐Zech, Ralf, additional, Wolf, Robert, additional, and Weigand, Jan J., additional

Published
2023
Full Text
View/download PDF

12. Total Survey Error in Practice

Author

Paul P. Biemer, Edith D. de Leeuw, Stephanie Eckman, Brad Edwards, Frauke Kreuter, Lars E. Lyberg, N. Clyde Tucker, Brady T. West, Paul P. Biemer, Edith de Leeuw, Stephanie Eckman, Brad Edwards, Frauke Kreuter, Lars E. Lyberg, N. Clyde Tucker, Brady T. West

Published
2017

16. Immunomodulatory treatment in unclassifiable interstitial lung disease: A retrospective study of treatment response

Author

Charlotte Hyldgaard, Sebastiano Torrisi, Sissel Kronborg Brix‐White, Thomas Skovhus Prior, Claudia Ganter, Elisabeth Bendstrup, and Michael Kreuter

Subjects
Pulmonary and Respiratory Medicine, lung fibrosis, pulmonary function, Vital Capacity, rare lung disease, Tidal Volume, Humans, Lung Diseases, Interstitial/drug therapy, immunomodulatory therapy, unclassifiable interstitial lung disease, Lung/diagnostic imaging, Retrospective Studies
Abstract

Background and Objective: The optimal management of unclassifiable Interstitial lung disease (ILD) remains a challenge. The aim of this study was to describe pulmonary function trajectories for patients treated with immunomodulatory therapy and for untreated patients. Methods: Clinical information and treatment data were obtained retrospectively at two ILD centres. Pulmonary function data were analysed using (1) mixed effects linear regression models with and without clinical covariates and (2) propensity score matching using gender, age, physiology (GAP) stage, smoking and presence of ground glass opacities. Results: Sixty-five percent of the 249 patients included received corticosteroids and/or other immunomodulators. Treated patients had lower forced vital capacity (FVC) (72% vs. 83% predicted) and diffusing capacity for carbon monoxide (DLco) (44% vs. 60% predicted). In mixed effects linear regression, the adjusted change in FVC was −0.22%, [−0.34; −0.11], and −0.15% [−0.28;-0.012] for DLco. The difference in pulmonary function decline between treated and untreated patients was insignificant, −0.082% per month, [−0.28; 0.11], p = 0.10 for FVC and −0.14% per month, [−0.36; 0.079], p = 0.15, for DLco. In propensity score matched analysis, the difference in change in FVC was 0.039% per month, p = 0.12, and for DLco, 0.0085% per month, p = 0.7. Conclusion: The pulmonary function trajectories for treated and untreated patients were parallel, despite treated patients having more severe disease at baseline. The persisting differences between the groups suggest no overall effect, although improvement or stabilization may be seen in some patients. Prospective studies are needed to define subsets of patients with unclassifiable interstitial lung disease and their optimal management.

Published
2022

17. S1‐Leitlinie: Kaposi‐Sarkom

Author

Stefan, Esser, Helmut, Schöfer, Christian, Hoffmann, Johannes, Claßen, Alexander, Kreuter, Ulrike, Leiter, Mark, Oette, Jürgen C, Becker, Mirjana, Ziemer, Franz, Mosthaf, Judith, Sirokay, Selma, Ugurel, Anja, Potthoff, Doris, Helbig, Erhard, Bierhoff, Thomas F, Schulz, Norbert H, Brockmeyer, and Stephan, Grabbe

Subjects
Humans, HIV Infections, Dermatology
Abstract

Das Kaposi-Sarkom (KS) ist eine seltene, maligne, von lymphatischen Endothelzellen ausgehende, multilokuläre Gefäßerkrankung, die vor allem Haut und Schleimhäute, aber auch das lymphatische System und innere Organe wie den Gastrointestinaltrakt, die Lunge oder die Leber befallen kann. Fünf epidemiologische Subtypen des KS mit variablem klinischem Verlauf und unterschiedlicher Prognose werden unterschieden, die in spezifischen Populationen vermehrt auftreten: (1) klassisches KS, (2) iatrogenes KS bei Immunsuppression, (3) endemisches (afrikanisches) lymphadenopathisches KS, (4) epidemisches, HIV-assoziiertes KS und mit einem Immunrekonstitutions-Inflammations-Syndrom (IRIS) assoziiertes KS und (5) KS bei Männern, die Sex mit Männern haben (MSM) ohne HIV-Infektion. Diese interdisziplinäre Leitlinie fasst aktuelle praxisrelevante Empfehlungen zu Diagnostik und Therapie der verschiedenen Formen des KS zusammen. Die in dieser Kurzleitlinie genannten Empfehlungen werden in der Langfassung der Leitlinie (Online-Version des JDDG) detaillierter ausgeführt.

Published
2022

20. Monkeypox infection with concomitant penile lymphoedema

Author

Kreuter, Alexander, Grossmann, Mona, Mueller, Valentina Laura, Michalowitz, Alena-Lioba, Oellig, Frank, Silling, Steffi, Heger, Eva, Wieland, Ulrike, Kreuter, Alexander, Grossmann, Mona, Mueller, Valentina Laura, Michalowitz, Alena-Lioba, Oellig, Frank, Silling, Steffi, Heger, Eva, and Wieland, Ulrike

Published
2023

27. Zunahme des atypischen Fibroxanthoms und pleomorphen dermalen Sarkoms: eine retrospektive Analyse vier deutscher Hauttumorzentren

Author

Kuntz, Thomas, primary, Siebdrath, Julian, additional, Hofmann, Silke C., additional, Baltaci, Mehmet, additional, Schaller, Jörg, additional, Hellmich, Martin, additional, von Goltzheim, Luise Stach, additional, Assaf, Chalid, additional, Oellig, Frank, additional, Michalowitz, Alena‐Lioba, additional, Helbig, Doris, additional, and Kreuter, Alexander, additional

Published
2022
Full Text
View/download PDF

30. Increase of atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective analysis of four German skin cancer centers

Author

Kuntz, Thomas, primary, Siebdrath, Julian, additional, Hofmann, Silke C., additional, Baltaci, Mehmet, additional, Schaller, Jörg, additional, Hellmich, Martin, additional, von Goltzheim, Luise Stach, additional, Assaf, Chalid, additional, Oellig, Frank, additional, Michalowitz, Alena‐Lioba, additional, Helbig, Doris, additional, and Kreuter, Alexander, additional

Published
2022
Full Text
View/download PDF

34. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe

Author

Karampitsakos, Theodoros, primary, Spagnolo, Paolo, additional, Mogulkoc, Nesrin, additional, Wuyts, Wim A., additional, Tomassetti, Sara, additional, Bendstrup, Elisabeth, additional, Molina‐Molina, Maria, additional, Manali, Effrosyni D., additional, Unat, Ömer Selim, additional, Bonella, Francesco, additional, Kahn, Nicolas, additional, Kolilekas, Lykourgos, additional, Rosi, Elisabetta, additional, Gori, Leonardo, additional, Ravaglia, Claudia, additional, Poletti, Venerino, additional, Daniil, Zoe, additional, Prior, Thomas Skovhus, additional, Papanikolaou, Ilias C., additional, Aso, Samantha, additional, Tryfon, Stavros, additional, Papakosta, Despoina, additional, Tzilas, Vasillios, additional, Balestro, Elisabetta, additional, Papiris, Spyridon, additional, Antoniou, Katerina, additional, Bouros, Demosthenes, additional, Wells, Athol, additional, Kreuter, Michael, additional, and Tzouvelekis, Argyris, additional

Published
2022
Full Text
View/download PDF

35. Characterisation of anal intraepithelial neoplasia and anal cancer in <scp>HIV</scp> ‐positive men by immunohistochemical markers p16, Ki‐67, <scp>HPV‐E4</scp> and <scp>DNA</scp> methylation markers

Author

Wim Quint, Alexander Kreuter, Jan M. Prins, Renske D.M. Steenbergen, Henry J. C. de Vries, Chris J.L.M. Meijer, Ramon P. van der Zee, Miekel M. van de Sandt, and Tamzin Cuming

Subjects
Cancer Research, Pathology, medicine.medical_specialty, biology, business.industry, Anal Squamous Cell Carcinoma, Cancer, Methylation, medicine.disease, Malignant transformation, Oncology, Ki-67, DNA methylation, biology.protein, Biomarker (medicine), Medicine, Anal cancer, business
Abstract

Human papillomavirus (HPV)-induced anal intraepithelial neoplasia (AIN, graded 1-3) is highly prevalent in HIV-positive (HIV+) men who have sex with men (MSM), but only a minority of lesions progresses to cancer. Our study aimed to characterise comprehensively anal tissue samples from a cross-sectional series (n = 104) of HIV+ MSM and longitudinal series (n = 40) of AIN2/3 progressing to cancer using different biomarkers. The cross-sectional series consisted of 8 normal, 26 AIN1, 45 AIN2, 15 AIN3 and 10 anal squamous cell carcinoma. Tissue sections were immunohistochemically (IHC) stained for p16 (viral transformation marker), Ki-67 (cellular proliferation marker) and HPV-E4 (viral production marker). We evaluated the expression of IHC markers and compared it with DNA methylation, a marker for malignant transformation. E4 positivity decreased, whereas p16 and Ki-67 scores and methylation marker positivity increased (P values

Published
2021

36. S2k‐Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes – Teil 1: Klassifikation, Diagnostik, Prävention und Aktivitätsscores

Author

Lisa Eisert, Claudia Günther, Alexander Kreuter, Ulf Müller-Ladner, Annegret Kuhn, Alexander Nast, Ivan Foeldvari, Jörg Wenzel, Christof Iking-Konert, Falk Ochsendorf, Miriam Zidane, Matthias F. Schneider, Rebecca Fischer-Betz, Klaus Tenbrock, Margitta Worm, and Michael Sticherling

Subjects
business.industry, Medicine, Dermatology, business
Published
2021

37. Changes in drinking days among United States adults during the COVID‐19 pandemic

Author

Kira E. Riehm, Emily J. Smail, Frauke Kreuter, Jeremy C. Kane, Courtney D. Nordeck, Johannes Thrul, Luther G. Kalb, Calliope Holingue, Cindy B. Veldhuis, Renee M. Johnson, and Elizabeth A. Stuart

Subjects
Panel survey, 2019-20 coronavirus outbreak, Census Region, Coronavirus disease 2019 (COVID-19), Poverty, business.industry, Ethnic group, 030508 substance abuse, Medicine (miscellaneous), Poverty status, 03 medical and health sciences, Psychiatry and Mental health, 0302 clinical medicine, Pandemic, Medicine, 030212 general & internal medicine, 0305 other medical science, business, Demography
Abstract

AIMS: To examine changes in drinking behavior among United States (US) adults between March 10 and July 21, 2020, a critical period during the COVID-19 pandemic. DESIGN: Longitudinal, internet-based panel survey. SETTING: The Understanding America Study (UAS), a nationally representative panel of US adults age 18 or older. PARTICIPANTS: A total of 4298 US adults who reported alcohol use. MEASUREMENTS: Changes in number of reported drinking days from March 11, 2020 through July 21, 2020 in the overall sample and stratified by sex, age, race/ethnicity, household structure, poverty status, and census region. FINDINGS: Compared with March 11, the number of drinking days per week was significantly higher on April 1 by an average of 0.36 days (95% CI = 0.30, 0.43), on May 1 by an average of 0.55 days (95% CI = 0.47, 0.63), on June 1 by an average of 0.41 days (95% CI = 0.33, 0.49), and on July 1 by an average of 0.39 days (95% CI = 0.31, 0.48). Males, White participants, and older adults reported sustained increases in drinking days, whereas female participants and individuals living under the federal poverty line had attenuated drinking days in the latter part of the study period. CONCLUSIONS: Between March and mid-July 2020, adults in the United States reported increases in the number of drinking days, with sustained increases observed among males, White participants, and older adults.

Published
2021

40. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial

Author

Maher, Toby M., Mayes, Maureen D., Michael, Kreuter, Volkmann, Elizabeth R., Martin, Aringer, Ivan, Castellvi, Cutolo, Maurizio, Christian, Stock, Nils, Schoof, Margarida, Alves, Ganesh, Raghu, and the SENSCIS Trial Investigators

Subjects
Adult, Male, medicine.medical_specialty, Vital capacity, Indoles, Full Length, Immunology, Placebo-controlled study, Systemic Sclerosis, Placebo, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, FEV1/FVC ratio, 0302 clinical medicine, Double-Blind Method, Rheumatology, Internal medicine, Humans, Immunology and Allergy, Medicine, 030212 general & internal medicine, Lung, Protein Kinase Inhibitors, Aged, Scleroderma, Systemic, business.industry, Minimal clinically important difference, Hazard ratio, Middle Aged, respiratory system, Confidence interval, respiratory tract diseases, Treatment Outcome, 030228 respiratory system, chemistry, Disease Progression, Female, Nintedanib, Lung Diseases, Interstitial, business, circulatory and respiratory physiology
Abstract

Objective In the SENSCIS trial in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% versus placebo. This study was undertaken to investigate the effects of nintedanib on categorical changes in FVC and other measures of ILD progression. Methods In post hoc analyses, we assessed the proportions of subjects with categorical changes in FVC % predicted at week 52 and the time to absolute decline in FVC of ≥5% predicted or death and absolute decline in FVC of ≥10% predicted or death. Results A total of 288 subjects received nintedanib and 288 subjects received placebo. At week 52, in subjects treated with nintedanib and placebo, respectively, 55.7% and 66.3% had any decline in FVC % predicted, 13.6% and 20.1% had a decline in FVC of >5% to ≤10% predicted, and 3.5% and 5.2% had a decline in FVC of >10% to ≤15% predicted; 34.5% and 43.8% had a decrease in FVC of ≥3.3% predicted (proposed minimal clinically important difference [MCID] for worsening of FVC), while 23.0% and 14.9% had an increase in FVC of ≥3.0% predicted (proposed MCID for improvement in FVC). Over 52 weeks, the hazard ratio (HR) for an absolute decline in FVC of ≥5% predicted or death with nintedanib versus placebo was 0.83 (95% confidence interval [95% CI] 0.66-1.06) (P = 0.14), and the HR for an absolute decline in FVC of ≥10% predicted was 0.64 (95% CI 0.43-0.95) (P = 0.029). Conclusion These results suggest that nintedanib has a clinically relevant benefit on the progression of SSc-ILD.

Published
2021

43. S1 Guidelines for the Kaposi Sarcoma

Author

Esser, Stefan, primary, Schöfer, Helmut, additional, Hoffmann, Christian, additional, Claßen, Johannes, additional, Kreuter, Alexander, additional, Leiter, Ulrike, additional, Oette, Mark, additional, Becker, Jürgen C., additional, Ziemer, Mirjana, additional, Mosthaf, Franz, additional, Sirokay, Judith, additional, Ugurel, Selma, additional, Potthoff, Anja, additional, Helbig, Doris, additional, Bierhoff, Erhard, additional, Schulz, Thomas F., additional, Brockmeyer, Norbert H., additional, and Grabbe, Stephan, additional

Published
2022
Full Text
View/download PDF

44. S1‐Leitlinie: Kaposi‐Sarkom

Author

Esser, Stefan, primary, Schöfer, Helmut, additional, Hoffmann, Christian, additional, Claßen, Johannes, additional, Kreuter, Alexander, additional, Leiter, Ulrike, additional, Oette, Mark, additional, Becker, Jürgen C., additional, Ziemer, Mirjana, additional, Mosthaf, Franz, additional, Sirokay, Judith, additional, Ugurel, Selma, additional, Potthoff, Anja, additional, Helbig, Doris, additional, Bierhoff, Erhard, additional, Schulz, Thomas F., additional, Brockmeyer, Norbert H., additional, and Grabbe, Stephan, additional

Published
2022
Full Text
View/download PDF

45. Increase of atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective analysis of four German skin cancer centers

Author

Kuntz, Thomas, Siebdrath, Julian, Hofmann, Silke C., Baltaci, Mehmet, Schaller, Joerg, Hellmich, Martin, von Goltzheim, Luise Stach, Assaf, Chalid, Oellig, Frank, Michalowitz, Alena-Lioba, Helbig, Doris, Kreuter, Alexander, Kuntz, Thomas, Siebdrath, Julian, Hofmann, Silke C., Baltaci, Mehmet, Schaller, Joerg, Hellmich, Martin, von Goltzheim, Luise Stach, Assaf, Chalid, Oellig, Frank, Michalowitz, Alena-Lioba, Helbig, Doris, and Kreuter, Alexander

Abstract

Background and objectives: In recent years, considerable insight has been gained into the pathogenesis, diagnosis and treatment of cutaneous sarcomas, including atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). Both entities have shown increasing incidence rates in the last decade. This study was initiated to evaluate how these new insights impact the number of diagnoses of AFX/PDS compared to other cutaneous sarcoma entities. Patients and methods: In a retrospective study of four German skin cancer centers, all histopathological reports of cutaneous sarcomas (AFX, PDS, dermatofibrosarcoma protuberans, cutaneous leiomyosarcoma, angiosarcoma, and Kaposi sarcoma) con-firmed by board-certified dermatopathologists were analyzed during a time-period of seven years (2013-2019). Additionally, utilization of immunohistochemical markers (including pan-cytokeratin, S100, desmin, CD34, CD10, procollagen-1, CD99, CD14, and CD68) as an adjunct to diagnose AFX/PDS was recorded. Results: Overall, 255 cutaneous sarcomas were included in the present study. The diagnosis of a cutaneous sarcoma has consequently risen from 2013 to 2019 (from 16 to 52 annual cases). The results of AFX/PDS revealed 4.6 times more diagnoses in 2019 than in 2013. Atypical fibroxanthoma represented the most common subtype, display-ing 49.3 % of all diagnosed cutaneous sarcomas. Additionally, the increase of AFX/PDS was linked to the use of immunohistochemistry, with specific immunohistochemical markers used in 57.1 % of cases in 2013 compared to 100 % in 2019. Conclusions: This retrospective study of four German skin cancer centers demonstrates a substantial rise of AFX/PDS, possibly due to recently established diagnostic and terminology standards. This rise is probably linked to increased utilization of specific immunohistochemical markers. Atypical fibroxanthoma/PDS may be more common than previously thought and seems to represent the most frequent cuta-neous sarcoma subtype.

Published
2022

47. S1 Guidelines for the Kaposi Sarcoma

Author

Esser, Stefan, Schoefer, Helmut, Hoffmann, Christian, Classen, Johannes, Kreuter, Alexander, Leiter, Ulrike, Oette, Mark, Becker, Juergen C., Ziemer, Mirjana, Mosthaf, Franz, Sirokay, Judith, Ugurel, Selma, Potthoff, Anja, Helbig, Doris, Bierhoff, Erhard, Schulz, Thomas F., Brockmeyer, Norbert H., Grabbe, Stephan, Esser, Stefan, Schoefer, Helmut, Hoffmann, Christian, Classen, Johannes, Kreuter, Alexander, Leiter, Ulrike, Oette, Mark, Becker, Juergen C., Ziemer, Mirjana, Mosthaf, Franz, Sirokay, Judith, Ugurel, Selma, Potthoff, Anja, Helbig, Doris, Bierhoff, Erhard, Schulz, Thomas F., Brockmeyer, Norbert H., and Grabbe, Stephan

Abstract

Kaposi's sarcoma (KS) is a rare, malignant, multilocular vascular disease originating from lymphatic endothelial cells that can primarily affect the skin and mucous membranes, but also the lymphatic system and internal organs such as the gastrointestinal tract, lungs or liver. Five epidemiological subtypes of KS with variable clinical course and prognosis are distinguished, with increased incidence in specific populations: (1) Classical KS, (2) Iatrogenic KS in immunosuppression, (3) Endemic (African) lymphadenopathic KS, (4) Epidemic, HIV-associated KS and KS associated with immune reconstitution inflammatory syndrome (IRIS), and (5) KS in men who have sex with men (MSM) without HIV infection. This interdisciplinary guideline summarizes current practice-relevant recommendations on diangostics and therapy of the different forms of KS. The recommendations mentioned in this short guideline are elaborated in more detail in the extended version of the guideline (online format of the JDDG).

Published
2022

49. Relevante Aspekte zur kutanen Leishmaniose auf Mallorca

Author

Burmann, Sven‐Niklas, primary, Sunderkötter, Cord, additional, Böer‐Auer, Almut, additional, Oellig, Frank, additional, Fischer, Marcellus, additional, Bogdan, Christian, additional, Michalowitz, Alena‐Lioba, additional, and Kreuter, Alexander, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results